| Enzo |
ALX-158-011-M001 |
Humanin (human)
|
1mg |
|
|
| Enzo |
ALX-158-011-MC05 |
Humanin (human)
|
0.5mg |
|
|
| Enzo |
ALX-157-001-M250 |
L Glutathione (oxidized form)
|
250mg |
|
|
| Enzo |
ALX-157-002-G025 |
L Glutathione (reduced form)
|
25g |
|
|
| Enzo |
ALX-157-002-G005 |
L Glutathione (reduced form)
|
5g |
|
|
| Enzo |
ALX-157-003-PC05 |
Galanin (human)
|
0.5mg* |
|
|
| Enzo |
ALX-157-003-P001 |
Galanin (human)
|
1mg* |
|
|
| Enzo |
ALX-157-010-MC01 |
Guanylin (human)
|
0.1mg |
|
|
| Enzo |
ALX-157-011-MC01 |
Guanylin (rat, mouse)
|
0.1mg |
|
|
| Enzo |
ALX-157-021-MC05 |
Ghrelin (human)
|
0.5mg |
|
|
| Enzo |
ALX-157-021-M001 |
Ghrelin (human)
|
1mg |
|
|
| Enzo |
ALX-157-001-G001 |
L Glutathione (oxidized form)
|
1g |
|
|
| Enzo |
ALX-155-022-M001 |
EGF receptor (human) (651-658) (N-Myristoylated)
|
1mg |
|
|
| Enzo |
ALX-155-023-M005 |
EGF receptor (human) (652-657)
|
5mg |
|
|
| Enzo |
ALX-155-023-M001 |
EGF receptor (human) (652-657)
|
1mg |
|
|
| Enzo |
ALX-155-037-M001 |
Extracellular death factor
|
1mg |
|
|
| Enzo |
ALX-157-001-G005 |
L Glutathione (oxidized form)
|
5g |
|
|
| Enzo |
ALX-155-016-PC05 |
ET receptor antagonist [PD 145,065]
|
0.5mg* |
|
|
| Enzo |
ALX-155-017-P001 |
ET A receptor antagonist [FR 139317]
|
1mg* |
|
|
| Enzo |
ALX-155-017-PC05 |
ET A receptor antagonist [FR 139317]
|
0.5mg* |
|
|
| Enzo |
ALX-155-018-MC05 |
ET B receptor antagonist [RES-701-1]
|
0.5mg |
|
|
| Enzo |
ALX-155-018-M001 |
ET B receptor antagonist [RES-701-1]
|
1mg |
|
|
| Enzo |
ALX-155-022-M005 |
EGF receptor (human) (651-658) (N-Myristoylated)
|
5mg |
|
|
| Enzo |
ALX-155-021-M001 |
EGF receptor (human) (651-658)
|
1mg |
|
|
| Enzo |
ALX-155-020-M001 |
ET B receptor antagonist . sodium salt
|
1mg |
|
|
| Enzo |
ALX-155-016-P001 |
ET receptor antagonist [PD 145,065]
|
1mg* |
|
|
| Enzo |
ALX-155-020-MC05 |
ET B receptor antagonist . sodium salt
|
0.5mg |
|
|
| Enzo |
ALX-155-012-PC05 |
ET A receptor antagonist [JKC-301]
|
0.5mg* |
|
|
| Enzo |
ALX-155-012-P001 |
ET A receptor antagonist [JKC-301]
|
1mg* |
|
|
| Enzo |
ALX-155-011-P001 |
ET A receptor antagonist [BQ-610]
|
1mg* |
|
|
| Enzo |
ALX-155-003-PC05 |
Endothelin 3 (human, rat, pig)
|
0.5mg* |
|
|
| Enzo |
ALX-155-003-PC01 |
Endothelin 3 (human, rat, pig)
|
0.1mg* |
|
|
| Enzo |
ALX-155-004-P005 |
ET A receptor antagonist [BQ-123] . sodium salt
|
5mg* |
|
|
| Enzo |
ALX-155-004-P001 |
ET A receptor antagonist [BQ-123] . sodium salt
|
1mg* |
|
|
| Enzo |
ALX-155-007-PC05 |
ET B receptor antagonist [IRL-1038]
|
0.5mg* |
|
|
| Enzo |
ALX-155-007-P001 |
ET B receptor antagonist [IRL-1038]
|
1mg* |
|
|
| Enzo |
ALX-155-008-PC05 |
ET receptor antagonist [PD 142,893]
|
0.5mg* |
|
|
| Enzo |
ALX-155-008-P001 |
ET receptor antagonist [PD 142,893]
|
1mg* |
|
|
| Enzo |
ALX-155-001-P001 |
Endothelin 1 (human, mouse, rat, pig, bovine, dog)
|
1mg* |
|
|
| Enzo |
ALX-155-001-PC05 |
Endothelin 1 (human, mouse, rat, pig, bovine, dog)
|
0.5mg* |
|
|
| Enzo |
ALX-155-002-PC01 |
Endothelin 2 (human, pig, dog)
|
0.1mg* |
|
|
| Enzo |
ALX-153-012-M001 |
Cyclin dependent kinase 2 inhibitor
|
1mg |
|
|
| Enzo |
ALX-153-055-G001 |
Carnosine
|
1g |
|
|
| Enzo |
ALX-153-064-M001 |
Caveolin 1 scaffolding domain peptide
|
1mg |
|
|
| Enzo |
ALX-153-064-M005 |
Caveolin 1 scaffolding domain peptide
|
5mg |
|
|
| Enzo |
ALX-153-066-C100 |
Blocking peptide for CCR3 (mouse) pAb (Prod. No. ALX-210-641)
|
100µg |
|
|
| Enzo |
ALX-155-001-PC01 |
Endothelin 1 (human, mouse, rat, pig, bovine, dog)
|
0.1mg* |
|
|
| Enzo |
ALX-153-003-M005 |
Casein kinase 2 substrate
|
5mg |
|
|
| Enzo |
ALX-153-003-M001 |
Casein kinase 2 substrate
|
1mg |
|
|
| Enzo |
ALX-152-006-M025 |
Bradykinin
|
25mg |
|
|